BioWorld Asia

Nov. 9, 2005

ExonHit Launches 6.5M IPO On Alternext Market

PARIS - ExonHit Therapeutics SA launched an initial public offering on the Alternext market of the Euronext stock exchange in Paris Nov. 8, hoping to raise 6.5 million (US$7.6 million). (BioWorld International) Read More

Raising Drug Prices In Europe Suggested As Solution For U.S.

Molecular Mimic Could Lead To New Immunotherapeutics

DOR Buying Gastrotech For $39M In Shares, Milestones

Fovea Brings In $25M For Retinal Disease Research

Ariana Signs With Pasteur Institute, Picks Up Funding

Vernalis Paying Mylan $23M For U.S. Rights To Apokyn

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 13, 2026.

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...